Methods: Retrospective, descriptive study of patients hospitalized with BM from January 2009-December 2015. We described the first epidemiological study of BM after the introduction of PCV in NIS in CR.
Results: 76 pts were enrolled. 49 pts (64.5%) were male and the median age at admission was 18 months; 63 pts (82.8%) under 24 months of age, but 20 pts (31.7%) were under 2 months of age. Mean length of stay was 19.3 days (range:16.07-22.59). Only 13.2% pts had at least 1 PCV dose. S. pneumoniae was isolated in 21/76 (27.6%), followed by S. agalactiae in 20/76 (26.3%) and E. coli 13/76 (17.1%). N. meningitidis was not isolated during the study period. Only 9/21 pneumococcal isolates were typified: vaccine-serotypes 5, 6B, 7F and 14 were found in 3/9 pts (33.3%) and in 1/9 pts (11.1%) each, respectively; non vaccine-serotypes 9N, 10A and 13 were found in 1/9 pts, each. All of the CSF pneumococcal isolates were penicillin-susceptible. Complications were documented in 24/76 pts (31.6%), been hypoacusia and neurological disabilities the most common. Mortality was documented in 4/76 (5.3%).
The incidence of BM in the post-PCV was dramatically reduced in comparison with the pre-PCV era, with a 54.7% reduction of all causes of BM and a 46.7% reduction in pneumococcal meningitis. Letality due to pneumococcal meningitis was also reduced from a 20% to a 14.3%.
Conclusion: In CR, BM is an important cause of high morbidity. Pneumococcal meningitis is still the leading cause of BM in our pediatric population, but a dramatic reduction in pneumococcal meningitis was observed after the introduction of PCV`s in our NIS. Mortality was lower than what is reported in industrialized countries.
M. L. Avila-Aguero, None
L. Avila, None
K. Camacho, None